DYAI - Dyadic International Inc Stock Price, Fair Value and News

1.65USD-0.01 (-0.60%)Delayed

Market Summary

USD1.65-0.01

Delayed

-0.60%

DYAI Stock Price

View Fullscreen

DYAI RSI Chart

DYAI Valuation

Market Cap

48.2M

Price/Earnings (Trailing)

-6.15

Price/Sales (Trailing)

21.39

Price/Free Cashflow

-8.53

DYAI Price/Sales (Trailing)

DYAI Profitability

Return on Equity

-173.8%

Return on Assets

-61.89%

Free Cashflow Yield

-11.72%

DYAI Fundamentals

DYAI Revenue

Revenue (TTM)

2.3M

Rev. Growth (Yr)

-7.69%

Rev. Growth (Qtr)

72.9%

DYAI Earnings

Earnings (TTM)

-7.8M

Earnings Growth (Yr)

-110.11%

Earnings Growth (Qtr)

Breaking Down DYAI Revenue

Last 7 days

13.8%

Last 30 days

-1.8%

Last 90 days

25%

Trailing 12 Months

-20.3%

How does DYAI drawdown profile look like?

DYAI Financial Health

Current Ratio

5.54

DYAI Investor Care

Shares Dilution (1Y)

1.48%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.3M	0	0	0
2023	3.3M	3.4M	3.0M	2.9M
2022	2.6M	2.3M	2.5M	2.9M
2021	0	2.2M	2.4M	2.3M
2020	1.6M	1.7M	1.7M	1.6M
2019	1.5M	1.7M	1.9M	1.7M
2018	892.7K	1.0M	1.2M	1.3M
2017	0	0	0	758.4K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Dyadic International Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 13, 2024	rawson ping wang	acquired	-	-	35,366	chief financial officer
Mar 13, 2024	hazelton joseph p	acquired	-	-	41,720	chief business officer
Mar 13, 2024	tchelet ronen	acquired	-	-	11,169	vp of research and bus. dvlpmt
Mar 13, 2024	emalfarb mark a	acquired	-	-	124,454	president and ceo
Jan 03, 2024	lucy patrick k.	acquired	-	-	27,174	-
Jan 03, 2024	buckland barry	acquired	-	-	27,174	-
Jan 03, 2024	kaye jack	acquired	-	-	27,174	-
Jan 03, 2024	tarnok michael p.	acquired	-	-	27,174	-
Jan 03, 2024	herbst seth	acquired	-	-	27,174	-
Jan 03, 2024	bose arindam	acquired	-	-	27,174	-

Which funds bought or sold DYAI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	reduced	-22.99	-18,317	72,729	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-78.49	-55,519	15,949	-%
May 15, 2024	Royal Bank of Canada	reduced	-1.47	-	7,000	-%
May 15, 2024	CAPTRUST FINANCIAL ADVISORS	unchanged	-	900	25,050	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-5.2	-154	9,095	-%
May 15, 2024	Northeast Financial Consultants Inc	unchanged	-	15,000	417,500	0.02%
May 15, 2024	AE Wealth Management LLC	added	19.7	9,878	31,897	-%
May 15, 2024	BARCLAYS PLC	unchanged	-	-	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-21.00	-	-%
May 15, 2024	MORGAN STANLEY	unchanged	-	27.00	758	-%

Are Funds Buying or Selling DYAI?

Are funds buying DYAI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DYAI

No. of Funds

Unveiling Dyadic International Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	bandera partners llc	5.4%	1,566,908	SC 13G/A
Feb 01, 2024	francisco trust under agreement dated february 28, 1996	12.32%	3,548,528	SC 13G/A
Mar 14, 2023	francisco trust under agreement dated february 28, 1996	12.42%	3,548,528	SC 13G/A
Feb 14, 2023	emalfarb mark a	17.7%	5,207,493	SC 13G/A
Feb 13, 2023	bandera partners llc	5.5%	1,566,908	SC 13G/A
Feb 28, 2022	francisco trust under agreement dated february 28, 1996	12.6%	3,548,528	SC 13G
Feb 14, 2022	bandera partners llc	5.6%	1,566,908	SC 13G
Feb 14, 2022	emalfarb mark a	17.9%	5,164,015	SC 13G/A
Feb 14, 2020	kitt barry m	5%	1,250,000	SC 13G/A

Recent SEC filings of Dyadic International Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	8-K	Current Report
May 07, 2024	EFFECT	EFFECT
Apr 24, 2024	ARS	ARS
Apr 24, 2024	DEF 14A	DEF 14A
Apr 24, 2024	DEFA14A	DEFA14A
Apr 24, 2024	S-3	S-3
Apr 15, 2024	4	Insider Trading
Apr 15, 2024	4	Insider Trading
Apr 15, 2024	4	Insider Trading

Peers (Alternatives to Dyadic International Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Dyadic International Inc News

Latest updates

Dyadic International Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-51.3%	334,617	686,535	397,060	837,159	978,052	743,726	879,597	658,553	648,427	313,290	692,929	937,092	345,917	416,361	524,271	315,372	433,168	454,507	390,874	402,527	686,875
Costs and Expenses	-13.8%	2,460,175	2,855,232	2,117,181	3,127,586	3,028,546	2,983,294	2,743,070	3,976,557	3,393,060	-1,884,149,848	4,016,931	4,804,166	2,614,741	2,992,669	3,322,280	2,697,894	2,369,512	2,397,918	3,352,388	2,843,847	2,452,210
S&GA Expenses	-100.0%	-	1,652,043	1,282,361	1,402,569	1,480,040	1,668,343	1,383,433	1,714,029	1,655,700	-774,523,337	1,692,837	1,747,614	1,312,682	1,643,493	1,475,232	1,653,392	1,164,981	1,056,196	1,870,678	1,428,067	1,284,531
R&D Expenses	-38.7%	522,723	852,797	716,351	917,552	810,566	584,120	743,585	1,830,798	1,342,862	-900,671,469	1,901,548	2,209,242	1,010,451	986,054	1,116,163	755,453	735,644	841,343	818,240	692,370	446,912
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	31,318	-	-	-	9,406	-	-	900	-1,006,157
Net Income	3.0%	-2,009,596	-2,071,798	-1,614,259	-2,152,960	-956,444	-2,146,425	-1,809,173	-3,287,995	-2,491,665	-4,213,860	-1,715,268	-3,846,174	-1,960,213	-2,499,499	-2,651,422	-2,214,139	-1,738,531	-1,698,384	-2,695,792	-2,175,258	-512,332
Net Income Margin	-48.4%	-3.48	-2.34	-2.32	-2.05	-2.52	-3.32	-4.72	-5.06	-4.73	-5.71	-4.52	-5.22	-5.82	-	-	-	-	-	-	-	-
Free Cashflow	-20.5%	-1,112,979	-923,380	-1,961,721	-1,654,716	-2,186,938	-1,681,762	-1,776,213	-1,775,417	-2,850,383	-2,635,064	-4,334,098	1,902,205,217	-1,286,984	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	54.3%	13.00	8.00	9.00	11.00	13.00	14.00	6,186	12,358	18,530	12,362	6,194	26.00	28.00	30.00	32.00	34.00	35.00	37.00	39.00	40.00	42.00
Current Assets	55.5%	13.00	8.00	9.00	11.00	13.00	13.00	15.00	17.00	16,241	21.00	24.00	26.00	28.00	30.00	32.00	34.00	33.00	36.00	36.00	38.00	41.00
Cash Equivalents	62.2%	11.00	7.00	7.00	6.00	6.00	6.00	7.00	9.00	12,419	16.00	14.00	14.00	13.00	21.00	22.00	12.00	5.00	5.00	5.00	5.00	4.00
Liabilities	248.9%	8.00	2.00	2.00	2.00	2.00	3.00	714	1,424	2,135	-	-	-	-	-	-	-	-	-	-	-	-
Current Liabilities	0.5%	2.00	2.00	1.00	2.00	2.00	2.00	2.00	3.00	1,826	3.00	2.00	3.00	3.00	2.00	2.00	2.00	1.00	2.00	1.00	1.00	1.00
Shareholder's Equity	-23.2%	5.00	6.00	8.00	9.00	11.00	11.00	13.00	14.00	16.00	18.00	22.00	23.00	26.00	28.00	30.00	32.00	34.00	36.00	37.00	39.00	41.00
Retained Earnings	-2.5%	-82.29	-80.28	-78.21	-76.59	-74.44	-73.48	-71.34	-69.53	-66,238	-63.75	-59.53	-57.82	-53.97	-50.68	-48.72	-46.22	-43.57	-41.35	-39.61	-37.91	-35.22
Additional Paid-In Capital	0.6%	106	105	105	104	104	103	103	102	101,523	101	100	100	99.00	98.00	98.00	97.00	97.00	96.00	96.00	95.00	95.00
Shares Outstanding	0.6%	29.00	29.00	29.00	29.00	29.00	29.00	28.00	28.00	28.00	28.00	28.00	28.00	28.00	27.00	-	-	-	-	-	-	-
Float	-	-	-	-	39.00	-	-	-	61.00	-	-	-	84.00	-	-	-	238	-	-	-	170	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-20.5%	-1,112	-923	-1,961	-1,654	-2,186	-1,681	-1,776	-1,775	-2,850	-2,635	-4,334	1,902,205	-1,906,513	-1,286	-1,383	-1,907	-1,996	-1,400	-1,540	-1,431	-1,409
Share Based Compensation	2.9%	306	298	281	334	331	481	500	455	454	460	457	-420,203	421,071	388	401	437	427	137	144	581	310
Cashflow From Investing	-2017.5%	-654	34.00	3,527	1,121	2,767	618	-1,309	-1,156	-520	4,500	4,006	5,780,656	-5,783,940	38.00	11,456	8,930	1,698	1,340	1,263	2,099	3,006
Cashflow From Financing	-	5,824	-	-	-	-	142	360	-	42.00	245	-590*	-114,813	115,800	25.00	67*	56.00	175	222	179	149	-
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

DYAI Income Statement

2024-03-31

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Total revenue	$ 334,617	$ 978,052
Costs and expenses:
Costs of research and development revenue	143,955	726,918
Research and development	522,723	810,566
General and administrative	1,788,594	1,480,040
Foreign currency exchange loss	4,903	11,022
Total costs and expenses	2,460,175	3,028,546
Loss from operations	(2,125,558)	(2,050,494)
Other income (expense):
Interest income	87,443	104,731
Gain on sale of Alphazyme	60,977	989,319
Total other income (expense), net	115,962	1,094,050
Net loss	$ (2,009,596)	$ (956,444)
Basic and diluted net loss per common share (in dollars per share)	$ (0.07)	$ (0.03)
Basic and diluted weighted-average common shares outstanding (in shares)	28,828,282	28,761,469
Nonrelated Party [Member]
Other income (expense):
Interest expense	$ (21,639)	$ 0
Related Party [Member]
Other income (expense):
Interest expense	(10,819)	0
Research and Development [Member]
Revenues:
Total revenue	334,617	933,934
License [Member]
Revenues:
Total revenue	$ 0	$ 44,118

DYAI Balance Sheet

2024-03-31

Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 10,569,814	$ 6,515,028
Short-term investment securities	1,468,002	748,290
Interest receivable	15,227	10,083
Accounts receivable	246,138	466,159
Prepaid expenses and other current assets	242,131	327,775
Total current assets	12,541,312	8,067,335
Non-current assets:
Operating lease right-of-use asset, net	129,519	141,439
Other assets	10,435	10,462
Total assets	12,681,266	8,219,236
Current liabilities:
Accounts payable	661,243	656,445
Accrued expenses	987,973	1,057,164
Deferred research and development obligations	534,018	490,113
Operating lease liability, current portion	49,551	48,059
Total current liabilities	2,262,119	2,251,781
Non-current liabilities:
Operating lease liability, net of current portion	75,894	88,870
Total liabilities	8,165,464	2,340,651
Commitments and contingencies (Note 5)
Stockholders’ equity:
Preferred stock, $.0001 par value: Authorized shares - 5,000,000; none issued and outstanding	0	0
Authorized shares - 100,000,000; issued shares - 41,440,316 and 41,064,563, outstanding shares - 29,186,814 and 28,811,061 as of March 31, 2024, and December 31, 2023, respectively	41,441	41,065
Additional paid-in capital	105,691,193	105,044,756
Treasury stock, shares held at cost - 12,253,502	(18,929,915)	(18,929,915)
Accumulated deficit	(82,286,917)	(80,277,321)
Total stockholders’ equity	4,515,802	5,878,585
Total liabilities and stockholders’ equity	12,681,266	8,219,236
Nonrelated Party [Member]
Current liabilities:
Accrued interest	19,556	0
Non-current liabilities:
Convertible notes, net of issuance costs	3,884,967	0
Related Party [Member]
Current liabilities:
Accrued interest	9,778	0
Non-current liabilities:
Convertible notes, net of issuance costs	$ 1,942,484	$ 0

About Dyadic International Inc

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. It utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus-like particles, protein antigens, ferritin nanoparticles, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to demonstrate the safety in humans of a protein produced from C1-cell protein production platform. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; and strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., as well as co-development and marketing agreement with Fermbox Bio Inc to design, Develop, and commercialize animal free alternative proteins and biomaterials The company was founded in 1979 and is headquartered in Jupiter, Florida.

CEO	Mr. Mark A. Emalfarb
WEBSITE	dyadic.com
INDUSTRY	Biotechnology

Dyadic International Inc Frequently Asked Questions

What is the ticker symbol for Dyadic International Inc? What does DYAI stand for in stocks?

DYAI is the stock ticker symbol of Dyadic International Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Dyadic International Inc (DYAI)?

As of Fri May 17 2024, market cap of Dyadic International Inc is 48.24 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DYAI stock?

You can check DYAI's fair value in chart for subscribers.

What is the fair value of DYAI stock?

You can check DYAI's fair value in chart for subscribers. The fair value of Dyadic International Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Dyadic International Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DYAI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Dyadic International Inc a good stock to buy?

The fair value guage provides a quick view whether DYAI is over valued or under valued. Whether Dyadic International Inc is cheap or expensive depends on the assumptions which impact Dyadic International Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DYAI.

What is Dyadic International Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, DYAI's PE ratio (Price to Earnings) is -6.15 and Price to Sales (PS) ratio is 21.39. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DYAI PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Dyadic International Inc's stock?

In the past 10 years, Dyadic International Inc has provided 0.015 (multiply by 100 for percentage) rate of return.